A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent Clear Cell Carcinoma of the Ovary Fallopian Tube or Peritoneum
-
- STATUS
- Not Recruiting
Summary
This phase II trial studies how well cabozantinib-s-malate works in treating patients with ovarian, fallopian tube, or primary peritoneal cavity cancer that has come back or is growing, spreading, or getting worse.
Description
The purpose of this study is to evaluate the anti-tumor activity of cabozantinib (XL184) (cabozantinib-s-malate) in women with persistent or recurrent clear cell ovarian cancer, based on the proportion of patients who survive progression-free for at least 6 months and the proportion who have objective tumor response (complete or partial).
Details
| Condition | Recurrent Clear Cell Carcinoma of the Ovary Fallopian Tube or Peritoneum |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX5565 |
| Last Modified on | 19 February 2024 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.